Abstract 404P
Background
Cancers in AYA is being recognized as a disenfranchised niche field with its own unique epidemiology, cancer biology, risk factors, treatment implications & the massive socio-economic impact it bears on this most economically productive age-group. There is a paucity of well-collated published data from developing countries. Our study has tried to compile & analyze the pattern of AYA cancers from a large rural tertiary care teaching-hospital in South India & compare it to the published national data.
Methods
We compiled & analyzed the burden of AYA cancers in terms of demographic & site distribution, proportion, histopathologic diagnosis & other parameters over Jan.2019 to Dec.2022 from the medical records of large rural tertiary care teaching-hospital in South India. We compared our data on AYA cancers vis-à-vis the published national statistics.
Results
A total of 7973 patients were diagnosed with cancer between Jan.2019 to Dec.2022, 983(12.3%) occurred in AYA. 544(55.3%) were females. 104(10.6%), 126(12.9%), 153(15.5%), 226(23%) & 374(38.0%) occurred in the 15-19, 20-24, 25-29, 30-34 & 35-39 age groups respectively. The most common cancer overall was hematolymphoid malignancy(201, 20.4%), followed by thyroid(188, 19.12%). The most common hematolymphoid malignancy is acute leukaemia followed by non-Hodgkin lymphoma. The most common thyroid neoplasm was papillary thyroid carcinoma. Other common malignancies included Breast(113, 11.5%), Oral cavity(79, 8%), Central nervous system(65, 6.6%) & lower gastrointestinal tract(48, 4.9%).
Conclusions
AYA cancers deserve organizational support, multicenter collaboration, & resource-appropriate treatment adaptations with dedicated survivorship clinics. Mapping the epidemiology of AYA cancers will help improve surveillance, further focussed research & collaboration, guide resource allocation and national health policies, thus ultimately improve survival.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Dr. Vishwapriya Mahadev Godkhindi.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
410P - The incidence and risk factors of kidney injury in patients receiving immune checkpoint inhibitors: A retrospective observational cohort study
Presenter: Thanawat Suksomboon
Session: Poster viewing 06
411P - Cost-effective analysis of the various cancer screening methods in the community: Pooled analysis of camps of 5 years from 2017-to 2022
Presenter: Suresh Attili
Session: Poster viewing 06
412P - Substance-P in the blood is related with the efficacy of aprepitant for targeted drug-induced refractory pruritus in Chinese malignancy population
Presenter: Fang Gao
Session: Poster viewing 06
413P - Association of concomitant medications on survival outcomes in cancer patients treated with immune checkpoint inhibitors: Analysis of health insurance review and assessment database
Presenter: Soojung Hong
Session: Poster viewing 06
414P - Lessons learnt from clinico-genomic profiling of families with Li Fraumeni Syndrome: The largest case series from the Indian setting
Presenter: Ghazal Tansir
Session: Poster viewing 06
415P - Small cell lung cancer: Epidemiological patterns and mutational profile in the United States
Presenter: Abdallah Allam
Session: Poster viewing 06
416P - Survival outcomes predicted by irAEs on 18F-FDG-PET in response to PD-1 antibody therapy in metastatic melanoma
Presenter: Sarah Lewis
Session: Poster viewing 06
417P - The activity and safety of anlotinib for patients with recurrent malignant glioma: A single-center, retrospective study
Presenter: Xudong Sun
Session: Poster viewing 06
418P - Mutational landscape of non-small cell lung cancer in the United States
Presenter: Mostafa Elsayed
Session: Poster viewing 06
419P - Breast arterial calcifications on mammogram and its clinical implications
Presenter: Pradeep Kumar Kistampally
Session: Poster viewing 06